
样式: 排序: IF: - GO 导出 标记为已读
-
Chronic Liver Disease and Cirrhosis Mortality Rates are Disproportionately Increasing in Younger Women in the US between 2000-2020 Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-28 Yazan Abboud, Anna G. Mathew, Mohamad Aghaie Meybodi, John Esli Medina, Saqr Alsakarneh, Catherine Choi, Yi Jiang, Nikolaos T. Pyrsopoulos
Background and aims Previous studies show that mortality from chronic liver disease (CLD) and cirrhosis is increasing in the U.S. However, there are limited data on sex-specific mortality trends by age, race, and geographical location. The aim of this study was to conduct a comprehensive time-trend analysis of liver disease related mortality rates in the National-Center-of-Health-Statistics(NCHS) database
-
AGA Clinical Practice Update on Appropriate and Tailored Polypectomy: Expert Review Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-28 Andrew P. Copland, Charles J. Kahi, Cynthia W. Ko, Gregory G. Ginsberg
Description In this Clinical Practice Update (CPU), we provide guidance on the appropriate use of different polypectomy techniques. We focus on polyps <2 cm in size that are most commonly encountered by the practicing endoscopist, including use of classification systems to characterize polyps and various polypectomy methods. We review characteristics of polyps that require complex polypectomy techniques
-
Adenomyomatous hyperplasia of the ampulla of Vater. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-28 Kento Yasumura, Ryuki Minami, Taro Ueo
Abstract not available
-
-
Elsewhere in the AGA Journals Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-23
Abstract not available
-
Editorial Board Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-23
Abstract not available
-
Table of Contents Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-23
Abstract not available
-
Blue Notes Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-23 Charles J. Kahi
Abstract not available
-
American Indian and Alaska Native Digestive Health: Challenges, Opportunities, and a Path Forward Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-23 Tyson A. Burningham, Lukejohn W. Day
Abstract not available
-
Exam 1: Endoscopy Unit Level Interventions to Improve Adenoma Detection Rate: A Systematic Review and Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-23
Abstract not available
-
A liver stiffness-based etiology-independent machine learning algorithm to predict hepatocellular carcinoma Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-21 Huapeng Lin, Guanlin Li, Adèle Delamarre, Sang Hoon Ahn, Xinrong Zhang, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Grace Lai-Hung Wong, Pong-Chi Yuen, Henry Lik-Yuen Chan, Stephen Lam Chan, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim, Terry Cheuk-Fung Yip
-
Prolonged gastrointestinal manifestations after recovery from COVID-19 Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-22 B. Joseph Elmunzer, Olafur S. Palsson, Nauzer Forbes, Ali Zakaria, Christian Davis, Andrew Canakis, Emad Qayed, Benjamin Bick, Swati Pawa, William M. Tierney, Caroline G. McLeod, Jason Taylor, Harsh Patel, Robin B. Mendelsohn, Gokul Bala, Ian Sloan, Ambreen A. Merchant, Zachary L. Smith, Morgan A. Sendzischew Shane, Olga C. Aroniadis, Douglas Drossman
Background Acute enteric infections are well known to result in long-term gastrointestinal disorders. While COVID-19 is principally a respiratory illness, it demonstrates significant gastrointestinal tropism, possibly predisposing to prolonged gut manifestations. We aimed to examine the long-term gastrointestinal impact of hospitalization with COVID-19. Methods Nested within a large-scale observational
-
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-20 Fernando Magro, Marijana Protic, Gert De Hertogh, Lai Shan Chan, Paul Pollack, Vipul Jairath, Hilde Carlier, Emily Hon, Brian G. Feagan, Noam Harpaz, Rish Pai, Walter Reinisch
Background & Aims Histologic evaluation of mucosal healing in Crohn’s disease (CD) is an evolving treatment target. We evaluated histologic outcomes for mirikizumab efficacy and associations with endoscopic and 1-year outcomes. Methods Biopsies from 1 ileal and 4 colonic segments were evaluated at Weeks 0, 12, and 52 from each 170 SERENITY participants. Criteria for the Weeks 12 and 52 histologic response
-
Accuracy of ChatGPT in Common Gastrointestinal Diseases: Impact for Patients and Providers Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-19 Anthony Kerbage, Joseph Kassab, Joseph El Dahdah, Carol A. Burke, Jean-Paul Achkar, Carol Rouphael
Abstract not available
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-17 Molla M. Wassie, Graeme P. Young, Jean M. Winter, Charles Cock, Erin L. Symonds
Abstract not available
-
Underuse of HCC Surveillance: Not a sign of cynicism Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-17 Amit G. Singal, Darine Daher, Karim Seif El Dahan, Ju Dong Yang, Nicole E. Rich, Neehar D. Parikh
Abstract not available
-
Reply to Dr. Butler Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-17 Chen Yuan, Kimmie Ng
Abstract not available
-
A Composite Morphometric Duodenal Biopsy Mucosal Scale for Celiac Disease Encompassing both Morphology and Inflammation Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-11 Jack A. Syage, Markku Mäki, Daniel A. Leffler, Jocelyn A. Silvester, Jennifer A. Sealey-Voyksner, Tsung-Teh Wu, Joseph A. Murray
Background & Aims Villus height to crypt depth ratio (Vh:Cd) and intraepithelial lymphocytes (IEL) are key measures of histology of the small intestine in celiac disease (CeD). While the field of CeD has advanced, there remains no broadly accepted measure of mucosal injury. We assessed whether a composite Vh:Cd and IEL scale (named VCIEL) can improve accuracy and statistical precision for assessing
-
Reply. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-09 Eric D. Shah, Emily V. Wechsler
Abstract not available
-
Bridging the Gap: Unraveling the Complex Ties between Digestive Diseases and Mental Health in the Elderly Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-07 Shubei He, Ying Peng, Qinglin Wei
Abstract not available
-
ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-10 Vipul Jairath, Andres Yarur, Mark T. Osterman, Alexandra James, Diane Balma, Shailly Mehrotra, Lili Yang, Vijay Yajnik, Rana M. Qasim Khan
-
Endoscopic transcecal appendectomy with a novel detachable over-the-scope clip Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-08 Fu Guan, Mingqing Zhang, Shengbing Wang
Abstract not available
-
Prevalence of Steatotic Liver Disease (MASLD, MetALD and ALD) in the United States: NHANES 2017-2020 Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-08 Markos Kalligeros, Athanasios Vassilopoulos, Stephanos Vassilopoulos, David W. Victor, Eleftherios Mylonakis, Mazen Noureddin
Abstract not available
-
AI-Powered Patient Education for Comprehensive and Individualized Understanding for Patients Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-07 Raseen Tariq, Sahil Khanna
Abstract not available
-
Peripheral blood IL5RA gene expression as a diagnostic biomarker for eosinophilic esophagitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-07 Jared A. Sninsky, Yihsuan S. Tsai, Siyao Liu, Joel S. Parker, David Corcoran, Evan S. Dellon
Abstract not available
-
AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-07 Jana G. Hashash, Christopher C. Thompson, Andrew Y. Wang
DESCRIPTION The purpose of this American Gastroenterological Association (AGA) Institute Rapid Clinical Practice Update (CPU) Communication is to review the available evidence and provide expert advice regarding the evolving management of patients taking GLP-1 receptor agonists prior to endoscopy. METHODS This CPU was commissioned and approved by the AGA Institute Clinical Practice Updates Committee
-
DEFINING OCCASIONAL CONSTIPATION: A STRAITJACKET? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-04 Gabrio Bassotti
Abstract not available
-
Buprenorphine versus diclofenac for pain relief in acute pancreatitis: A double-blinded randomized-controlled trial Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-03 Mayank Saini, Jayanta Samanta, Antriksh Kumar, Arup Choudhury, Jahnvi Dhar, Anudeep Jafra, Rajeev Chauhan, Gaurav Muktesh, Pankaj Gupta, Vikas Gupta, Thakur Deen Yadav, Rakesh Kochhar, Gabiele Capurso, Enrique De-Madaria, Antonio Facciorusso
Background While both non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are used for analgesia in acute pancreatitis (AP), the analgesic of choice is not known. We compared buprenorphine, an opioid, and diclofenac, an NSAID, for analgesia in AP. Methods In a double-blind randomized controlled trial, AP patients were randomized to receive IV diclofenac or IV buprenorphine. Fentanyl was used
-
Limited Impact of a Multifaceted Quality Improvement Intervention Upon Adherence to Pancreatitis Quality Metrics Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-03 Rajesh N. Keswani, Joshua Zimmerman, Barbara Buckley, Dharmesh Patel, Justin Boike, John Pandolfino
Abstract not available
-
The Evolving Landscape of Colorectal Cancer Screening and Colonoscopy Practice: Insights from the Japan Polyp Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-03 Han-Mo Chiu
Abstract not available
-
Assessing risk of index serrated polyps Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-02 Joseph C. Anderson, Lynn F. Butterly
The most recent US Multi Society Task Force (USMSTF) for Colorectal Cancer (CRC) post-polypectomy guidelines recommend surveillance intervals for sessile serrated lesions (SSLs) based on size, dysplasia, and number of index polyps.1 Large (>1 cm) hyperplastic polyps (HPs), which previously had a 10 year follow-up recommendation, now have a 3-5 year interval,2 However, most of the serrated polyp recommendations
-
Metoclopramide Nasal Spray in Women with Symptomatic Diabetic Gastroparesis: A Randomized, Double-blind, Placebo-controlled Phase 3 Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-02 Richard W. McCallum, Henry P. Parkman, Ronnie Fass, Bal R. Bhandari, Marilyn R. Carlson, Raymond D. Buck
Background & Aims Metoclopramide nasal spray (MNS) was developed as an alternative to oral metoclopramide. Prior phase 2 studies demonstrated efficacy in reducing symptoms in women, but not men with diabetic gastroparesis. The aim of this phase 3 study was to further determine the safety and efficacy of MNS compared to placebo in reducing symptoms of diabetic gastroparesis in women. Methods This US
-
Effect of real-time computer-aided polyp detection system (ENDO-AID) on adenoma detection in endoscopists-in-training: a randomized trial Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-11-02 Louis H.S. Lau, Jacky C.L. Ho, Jimmy C.T. Lai, Agnes H.Y. Ho, Claudia W.K. Wu, Vincent W.H. Lo, Carol M.S. Lai, Markus W. Scheppach, Felix Sia, Kyle H.K. Ho, Xiang Xiao, Terry C.F. Yip, Thomas Y.T. Lam, Hanson Y.H. Kwok, Heyson C.H. Chan, Rashid N. Lui, Ting-Ting Chan, Marc T.L. Wong, Man-Fung Ho, Rachel C.W. Ko, Philip W.Y. Chiu
-
Reply to the Letter to the Editor: “GLP-1 Receptor Agonist Treatment in Liver Cirrhosis” Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-31 Fu-Shun Yen, Chii-Min Hwu, Chih-Cheng Hsu
Abstract not available
-
Response to a Letter to the Editor by M.J. Warners and A.J. Bredenoord, concerning the article “Efficacy of Elimination Diets in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis”. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-31 Christoph Mayerhofer, Georg Friedrich Vogel
Abstract not available
-
BENEFITS OF PROKINETICS, GASTROPARESIS DIET, OR NEUROMODULATORS ALONE OR IN COMBINATION FOR SYMPTOMS OF GASTROPARESIS Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-30 William L. Hasler, Allen A. Lee, Baharak Moshiree, Brian C. Surjanhata, Satish Rao, Henry P. Parkman, Linda A. Nguyen, Irene Sarosiek, John M. Wo, Michael I. Schulman, Richard W. McCallum, Braden Kuo
Background and Aims Prokinetics have limited effectiveness for treating symptoms of gastroparesis. Thus, alternative or adjunct therapies like gastroparesis diets or neuromodulators are often prescribed. Their therapeutic benefits alone or in combination remain unclear. Methods 129 patients with symptoms of gastroparesis underwent wireless motility capsule gastric emptying time (GET) and gastric emptying
-
Unveiling the Hidden Cost: Evaluating Financial Implications in the Liver Cancer Screening Paradigm Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-30 Elizabeth S. Aby, Nneka N. Ufere
Abstract not available
-
Histological activity in inflammatory bowel disease and risk of serious infections: A nationwide study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-30 Karl Mårild, Jonas Söderling, Jordan Axelrad, Jonas Halfvarson, Anders Forss, Ola Olén, Jonas F. Ludvigsson, , Malin Olsson, Pär Myrelid, Henrik Hjortswang, Jonas Bengtsson, Hans Strid, Marie Andersson, Susanna Jäghult, Michael Eberhardson, Caroline Nordenvall, Jan Björk, Martin Rejler, Olof Grip, Pontus Karling
Background and aims Individuals with inflammatory bowel disease (IBD) are at increased risk of serious infections, but whether this risk varies by histological disease activity is unclear. Methods A national population-based study of 55,626 individuals diagnosed with IBD in 1990-2016 with longitudinal data on ileo-colorectal biopsies followed through 2016. Serious infections were defined as having
-
Sphingosine 1-Phosphate Receptor Modulators are Effective in Patients with Moderately to Severely Active Ulcerative Colitis and a Prior Biologic Exposure: A Meta-Analysis of Randomized Controlled Trials Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-30 Omar Mahmud, Asad Saulat Fatimi, Muhammad Umar Mahar, Arshia Jahangir, Manzar Abbas, Jeffrey A. Berinstein
Abstract not available
-
Significance of Crypt Atypia in Barrett’s Esophagus: A Clinical, Molecular and Outcome Study. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-24 Wang HH, Patil DT, Paulson TG, Grady WM, Odze RD
Background and Aims The aim of this study was to characterize baseline morphologic features of crypts in non-dysplastic Barrett’s esophagus (NDBE) and correlate them with DNA content abnormalities and risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Methods The morphologic features of non-dysplastic crypts in baseline biopsies from 212 BE patients (2956 biopsies)
-
Artificial intelligence chatbot shows multiple inaccuracies when responding to questions about eosinophilic esophagitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-24 Corey J. Ketchem, Kristle L. Lynch, Joy W. Chang, Evan S. Dellon
Abstract not available
-
Exam 2: Risk of Postcolonoscopy Thromboembolic Events: A Real-World Cohort Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23
Abstract not available
-
Breast Feeding and Increased Risk of Colon Cancer: What is the Missing Link? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-24 Ayokunle T. Abegunde
Abstract not available
-
Prevalence of Barrett’s Esophagus and Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-24 Bibek Saha, Kornpong Vantanasiri, Babu P. Mohan, Rohit Goyal, Nikita Garg, Danielle Gerberi, John B. Kisiel, Siddharth Singh, Prasad G. Iyer
Background and Aims While gastroesophageal reflux disease (GERD) symptoms are an essential criterion for Barrett’s esophagus (BE) screening in most gastroenterology society guidelines, a significant proportion of BE and esophageal adenocarcinoma (EAC) cases do not endorse them. In a systematic review and meta-analysis (SRM), we aimed to study the prevalence of BE/EAC in those with and without GERD
-
Multiple Negative Fecal Immunochemical Tests: Is Testing Really Better? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Alejandra Mijangos-Trejo, Jorge Aquino-Matus, Norberto Chávez-Tapia
Abstract not available
-
Diarrhea after Gastric Surgery: More Than Meets the Eye Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Jintong Chen, Yanni Huang, Chengdang Wang
Abstract not available
-
Gluten-Related Disorders from Bench to Bedside Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Claire L. Jansson-Knodell, Alberto Rubio-Tapia
Celiac disease, non-celiac gluten sensitivity, and wheat allergy comprise three of the main conditions with wheat and gluten-containing foods as the symptom trigger. Distinguishing between these entities can be daunting. In this review we compare and contrast celiac disease, non-celiac gluten sensitivity, and wheat allergy to allow clinicians to determine which diagnosis fits their patient to facilitate
-
Common Instances of Low-value Care in Inflammatory Bowel Diseases Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Siddharth Singh, Fernando S. Velayos, David T. Rubin
Value-based care focuses on improving the quality, effectiveness, and efficiency of healthcare while controlling costs. Low value care implies services or interventions that provide little or no benefit to patients, have the potential to cause harm, incur unnecessary cost to patients, or waste limited healthcare resources. In this review, we discuss common instances of low value care along the spectrum
-
Province-Wide Ascertainment of Lynch Syndrome in Manitoba Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Heidi Rothenmund, Lambert Pascal, Deirdre Khan, Christina Kim, Bhavya Sharma, Kim Serfas, Bernard Chodirker, Harminder Singh
Background & Aims We describe the experience of Lynch Syndrome (LS) diagnosis in the province of Manitoba, Canada over the last twenty years. Methods We performed a retrospective review of charts from the provincial Genetics clinic from January 1, 2000-May 31, 2023. We extracted data on individuals identified to carry a germline pathogenic or likely pathogenic LS gene variant, the mode of ascertainment
-
-
Editorial Board Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23
Abstract not available
-
Table of Contents Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23
Abstract not available
-
Blue Notes Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Charles J. Kahi
Abstract not available
-
Elsewhere in the AGA Journals Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23
Abstract not available
-
Working With Indigenous Community and Patient Partners Is Essential to Advance Gastroenterology and Hepatology Research: Perspectives From Canada Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Juan Nicolás Peña-Sánchez, Jessica Amankwah Osei, Ulrich Teucher, Melissa Tremblay, Sharyle Fowler
Abstract not available
-
Exam 1: HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23
Abstract not available
-
Real World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-23 Ravi S. Shah, Salam Bachour, Abel Joseph, Huijun Xiao, Ruishen Lyu, Hareem Syed, Terry Li, Shravya Pothula, Vall Vinaithirthan, Adel Hajj Ali, Sussel Contreras, Jessica H. Hu, Edward L. Barnes, Jordan E. Axelrad, Stefan D. Holubar, Miguel Regueiro, Benjamin L. Cohen, Benjamin H. Click
Background & Aims Preoperative risk stratification may help guide prophylactic biologic utilization for the prevention of postoperative Crohn's disease (CD) recurrence; however, there is limited data exploring and validating proposed clinical risk factors. We aimed to explore preoperative clinical risk profiles, quantify individual risk factors, and assess the impact of biologic prophylaxis on postoperative
-
Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-21 Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Chen-Hua Liu, Sih-Han Liao, Chun-Ming Hong, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
BACKGROUND AND AIMS Hepatitis B surface antigen (HBsAg) seroclearance is the goal of functional cure for hepatitis B virus (HBV) infection. However, the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on this favorable outcome remains unclear. METHODS Patients with chronic hepatitis B (CHB) were consecutively recruited. MASLD was defined by the newly proposed disease criteria
-
Snare tip soft coagulation vs argon plasma coagulation vs no margin treatment after large non-pedunculated colorectal polyp resection: a randomized trial Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-21 Douglas K. Rex, Gregory B. Haber, Mouen Khashab, Amit Rastogi, Muhammad K. Hasan, Christopher J. DiMaio, Nikhil A. Kumta, Satish Nagula, Stuart Gordon, Firas Al-Kawas, Jerome D. Waye, Hadie Razjouyan, Charles E. Dye, Matthew T. Moyer, Jeremiah Shultz, Rachel E. Lahr, Poi Yu Sofia Yuen, Rebekah Dixon, LaKeisha Boyd, Heiko Pohl
Background and Aims Thermal treatment of the defect margin after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal lesions reduces the recurrence rate. Both snare tip soft coagulation (STSC) and argon plasma coagulation (APC) have been used for thermal margin treatment, but there are few data directly comparing STSC to APC for this indication. Methods We performed a randomized
-
Monitoring of hepatocellular carcinoma … surveillance: reaching the horizon Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-10-20 Alain Braillon
Abstract not available